Targeting solid tumors via T cell receptor complementarity-determining region 3δ in an engineered antibody

Cancer Letters

Volumn 272, Issue 2, 2008, Pages 242-252

  Wang, Zhun ^a   Zhang, Tie ^a   Hu, Hongbo ^a   Zhang, Huiyuan ^a   Yang, Zhi ^b   Cui, Lianxian ^a   He, Wei ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

T cells; CDR3 grafted antibody; Immunotoxin; Solid tumors; Tumor targeting

Indexed keywords

CANCER ANTIBODY; CANCER ANTIBODY OT3; CANCER ANTIBODY OT3 DIPHTHERIA TOXIN CONJUGATE; CANCER ANTIBODY OT3 TC 99M; CISPLATIN; DIPHTHERIA TOXIN; HEAT SHOCK PROTEIN 60; IMMUNOTOXIN; INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR DELTA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY ENGINEERING; ARTICLE; CANCER CELL CULTURE; CANCER MODEL; COMPLEMENTARITY DETERMINING REGION; COMPLEMENTARITY DETERMINING REGION 3DELTA; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; FEMALE; GAMMADELTA T CELL; HUMAN; HUMAN CELL; ISOTOPE LABELING; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; RECTUM CARCINOMA; SOLID TUMOR; T LYMPHOCYTE; UTERINE CERVIX CARCINOMA;

ANIMALS; CELL LINE, TUMOR; COMPLEMENTARITY DETERMINING REGIONS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, SCID; NEOPLASMS; PROTEIN ENGINEERING; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; SURFACE PLASMON RESONANCE;

MURINAE; MUS MUSCULUS;

EID: 56149084688     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.07.015     Document Type: Article

References (32)

1. Ross J.S., Gray K., Gray G.S., Worland P.J., and Rolfe M. Anticancer antibodies. Am. J. Clin. Pathol. 119 (2003) 472-485
2. Reichert J.M., Rosensweig C.J., Faden L.B., and Dewitz M.C. Monoclonal antibody successes in the clinic. Nat. Biotechnol. 23 (2005) 1073-1078
3. Waldhauer I., and Steinle A. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res. 66 (2006) 2520-2526
4. Morgan R.A., Dudley M.E., Wunderlich J.R., Hughes M.S., Yang J.C., Sherry R.M., Royal R.E., Topalian S.L., Kammula U.S., Restifo N.P., Zheng Z., Nahvi A., de Vries C.R., Rogers-Freezer L.J., Mavroukakis S.A., and Rosenberg S.A. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314 (2006) 126-129
5. Hayday A.C. [γ][δ] cells: a right time and a right place for a conserved third way of protection. Annu. Rev. Immunol. 18 (2000) 975-1026
6. Yu S., He W., Chen J., Zhang F., and Ba D. Expansion and immunological study of human tumor infiltrating γ/δ T lymphocytes in vitro. Int. Arch. Allergy Immunol. 119 (1999) 31-37
7. Chen J., Niu H., He W., and Ba D. Antitumor activity of expanded human tumor-infiltrating γδ T lymphocytes. Int. Arch. Allergy Immunol. 125 (2001) 256-263
8. Zhang H., Hu H., Jiang X., He H., Cui L., and He W. Membrane HSP70: the molecule triggering γδ T cells in the early stage of tumorigenesis. Immunol. Invest. 34 (2005) 453-468
9. Xu C., Zhang H., Hu H., He H., Wang Z., Xu Y., Chen H., Cao W., Zhang S., Cui L., Ba D., and He W. γδ T cells recognize tumor cells via CDR3δ region. Mol. Immunol. 44 (2007) 302-310
10. Chen H., He X., Wang Z., Wu D., Zhang H., Xu C., He H., Cui L., Ba D., and He W. Identification of human T cell receptor γδ-recognized epitopes/proteins via CDR3δ peptide-based immunobiochemical strategy. J. Biol. Chem. 283 (2008) 12528-12537
11. Edelson P.J., and Cohn Z.A. Purification and cultivation of monocytes and macrophages. In: Bloom B.A., and David J.R. (Eds). Vitro Methods in Cell-Mediated and Tumor Immunity (1976), Academic Press, San Diego 333-340
12. Hara H., and Seon B.K. Complete suppression of in vivo growth of human leukemia cells by specific immunotoxins: nude mouse models. Proc. Natl. Acad. Sci. USA 84 (1987) 3390-3394
13. Knoll K., Wrasidlo W., Scherberich J.E., Gaedicke G., and Fischer P. Targeted therapy of experimental renal cell carcinoma with a novel conjugate of monoclonal antibody 138H11 and calicheamicin θI1. Cancer Res. 60 (2000) 6089-6094
14. Medzhitov R., Preston-Hurlburt P., and Janeway Jr. C.A. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388 (1997) 394-397
15. Karre K., Ljunggren H.G., Piontek G., and Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319 (1986) 675-678
16. Davis M.M., and Chien Y.H. T-cell antigen receptors. In: Paul W.E. (Ed). Fundamental Immunology (2006), Lippincott, Philadelphia, PA 422-480
17. Kabelitz D., Wesch D., and He W. Perspectives of γδ T cells in tumor immunology. Cancer Res. 67 (2007) 5-8
18. Maeurer M.J., Martin D., Walter W., Liu K., Zitvogel L., Halusczcak K., Rabinowich H., Duquesnoy R., Storkus W., and Lotze M.T. Human intestinal Vδ1+ lymphocytes recognize tumor cells of epithelial origin. J. Exp. Med. 183 (1996) 1681-1696
19. Groh V., Rhinehart R., Secrist H., Bauer S., Grabstein K.H., and Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc. Natl. Acad. Sci. USA 96 (1999) 6879-6884
20. Cosman D., Mullberg J., Sutherland C.L., Chin W., Armitage R., Fanslow W., Kubin M., and Chalupny N.J. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14 (2001) 123-133
21. Poggi A., Venturino C., Catellani S., Clavio M., Miglino M., Gobbi M., Steinle A., Ghia P., Stella S., Caligaris-Cappio F., and Zocchi M.R. Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res. 64 (2004) 9172-9179
22. Groh V., Wu J., Yee C., and Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419 (2002) 734-738
23. Marten A., Lilienfeld-Toal M., Buchler M.W., and Schmidt J. Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing γδ T cell cytotoxicity. Int. J. Cancer 119 (2006) 2359-2365
24. Bennouna J., Medioni J., Rolland F., Misset J.L., Campone M., Sicard H., Tiollier J., Romagne F., Douillard J.Y., and Calvo F. Phase I clinical trial of BromoHydrin PyroPhosphate, BrHPP (Phosphostim), a V{gamma}9V{delta}2 T lymphocytes agonist in combination with low dose Interleukin-2 in patients with solid tumors. J Clin Oncol (Meeting Abstracts) 23 (2005) 2536
25. Scotet E., Martinez L.O., Grant E., Barbaras R., Jeno P., Guiraud M., Monsarrat B., Saulquin X., Maillet S., Esteve J.P., Lopez F., Perret B., Collet X., Bonneville M., and Champagne E. Tumor recognition following Vγ9Vδ2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity 22 (2005) 71-80
26. Adams E.J., Chien Y.H., and Garcia K.C. Structure of a γδ T cell receptor in complex with the nonclassical MHC T22. Science 308 (2005) 227-231
27. Kaur I., Voss S.D., Gupta R.S., Schell K., Fisch P., and Sondel P.M. Human peripheral gamma delta T cells recognize hsp60 molecules on Daudi Burkitt's lymphoma cells. J. Immunol. 150 (1993) 2046-2055
28. Adams G.P., and Weiner L.M. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23 (2005) 1147-1157
29. Billetta R., Hollingdale M.R., and Zanetti M. Immunogenicity of an engineered internal image antibody. Proc. Natl. Acad. Sci. USA 88 (1991) 4713-4717
30. Ghetie V., and Vitetta E.S. Chemical construction of immunotoxins. Mol. Biotechnol. 18 (2001) 251-268
31. Morimoto H., Safrit J.T., and Bonavida B. Synergistic effect of tumor necrosis factor-alpha- and diphtheria toxin-mediated cytotoxicity in sensitive and resistant human ovarian tumor cell lines. J. Immunol. 147 (1991) 2609-2616
32. Li Z., Yu T., Zhao P., and Ma J. Immunotoxins and cancer therapy. Cell Mol. Immunol. 2 (2005) 106-112